Improved Perfusion after Subcritical Ischemia in Muscle Flaps Treated with Vascular Endothelial Growth Factor
- 1 December 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 106 (7) , 1541-1546
- https://doi.org/10.1097/00006534-200012000-00015
Abstract
Vascular endothelial growth factor (VEGF), a potent endothelial mitogen, is secreted in ischemic tissue and plays a pivotal role in angiogenesis. We studied whether VEGF administered to a rat muscle flap at the time of ischemia induction would increase microcirculatory flow to the flap. The cremaster muscle flap was isolated on its neurovascular pedicle. Ischemia was induced by clamping the vascular pedicle, and 0.2 ml of either VEGF (0.1 μg) or vehicle (phosphate-buffered saline) was immediately infused into the muscle. After 4 or 6 hours, the clamps were released, and the cremaster was placed in a pocket in the medial thigh for 24 hours. The muscle was then dissected, and microcirculatory measurements were made under intravital microscopy. Six animals were used in each of the four groups. All flaps exposed to 6 hours of ischemia, the duration considered to be critical ischemia, had no significant microcirculatory flow, regardless of treatment with VEGF. In the 4-hour ischemia group, or subcritical ischemia group, red blood cell velocity in arterioles was 14 mm/sec in muscles treated with VEGF and 9 mm/sec in controls (p = 0.02), and capillary flow was 7 per high-power field in muscles treated with VEGF versus 2 per high-power field in controls (p = 0.0005). Thus, VEGF did not alter microcirculatory flow in a muscle flap exposed to critical ischemia, but it did enhance flow to a flap exposed to subcritical ischemia. (Plast. Reconstr. Surg. 106: 1541, 2000.)Keywords
This publication has 18 references indexed in Scilit:
- Effect of Vascular Endothelial Growth Factor (VEGF) on Survival of Random Extension of Axial Pattern Skin Flaps in the RatAnnals of Plastic Surgery, 1996
- Superoxide Radical: Controversies, Contradictions, and ParadoxesExperimental Biology and Medicine, 1995
- Vascular endothelial growth factor and its receptorsProgress in Growth Factor Research, 1994
- Vascular permeability factor (VPF, VEGF) in tumor biologyCancer and Metastasis Reviews, 1993
- Ischemia reperfusion injury: A reviewMicrosurgery, 1993
- Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of ProteinsEndocrine Reviews, 1992
- Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and NecrosisScience, 1990
- Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.Journal of Clinical Investigation, 1989
- Pharmacologic Modulation of Experimental Postischemic Hepatic FunctionAnnals of Surgery, 1989
- Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion.Journal of Clinical Investigation, 1988